

May 24, 2006  
AnGes MG, Inc.

**A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide**  
**-Covering Treatment for Atopic Dermatitis-**

AnGes MG, Inc. is pleased to announce that a medical-use patent for NFκB decoy covering the treatment of atopic dermatitis has been granted in Japan (JP3778357).

The patent covers a broad range of transdermal external medications of NFκB decoy and also “compositions” including NFκB decoy for the treatment of atopic dermatitis. The patent provides powerful support to the project currently being developed in collaboration with Alfresa Pharma Corporation.

AnGes MG has already filed patent applications for treatment for atopic dermatitis in the US and Europe in addition to Japan to cover global development activities.

Besides this patent, AnGes MG aims to establish intellectual property rights in line with the expansion of clinical indications by filing additional applications for use of NFκB decoy oligonucleotide in other diseases, including asthma, aneurysms, organ and vascular transplantation, psoriasis, and rheumatoid arthritis. A patent has already been granted (JP3474879) for use in the treatment of reperfusion disorder; postoperative aggravation from organ transplantations and surgery; post PTCA restenosis; cancer metastasis/invasion and cachexia.

AnGes MG is currently conducting phase I clinical trial of NFκB decoy oligonucleotide for atopic dermatitis. Patient registration has already been completed, and we are currently in the process of analyzing the results.